HTA of the Innovative Medicines in Germany
The Market Access of the innovative medicines, is monitored by both Regulators and Payers. To assess the new drugs; if they deliver a fair value for money. The remarkable recent discrepancies between both parties' requirements during the market entry process, represent a financial threat on the Pharmaceutical industry. The evolving restrictions would alter the industry motive to invest in Research and Development. Consequently, patients will not receive the appropriate medicines to win their battles against the developed ailments which may then contribute to a public health alarm.
CHF 47.90
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
V105:
Folgt in ca. 15 Arbeitstagen
Produktdetails
- ISBN: 978-620-2-06988-5
- EAN: 9786202069885
- Produktnummer: 37497441
- Verlag: LAP Lambert Academic Publishing
- Sprache: Englisch
- Erscheinungsjahr: 2017
- Seitenangabe: 88 S.
- Masse: H22.0 cm x B15.0 cm x D0.5 cm 149 g
- Abbildungen: Paperback
- Gewicht: 149
Über den Autor
I am a pharmaceutical professional with 10 years' experience in international pharma giants. I have worked for Pfizer, Johnson & Johnson, Boehringer Ingelheim and Sanofi. Until recently, I have executed a MSc degree in International Pharmacoeconomics and Health Economics offered by Cardiff University, United Kingdom.
Bewertungen
Anmelden